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A B S T R A C T
Background
De Quervain’s tenosynovitis is a disorder characterised by pain on the radial (thumb) side of the wrist and functional disability of the
hand. It can be treated by corticosteroid injection, splinting and surgery.
Objectives
To summarise evidence on the efficacy and safety of corticosteroid injections for de Quervain’s tenosynovitis.
Search methods
We searched the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2009,
Issue 2), MEDLINE (1966 to April 2009), EMBASE (1956 to April 2009), CINAHL (1982 to April 2009), AMED (1985 to April
2009), DARE, Dissertation Abstracts and PEDro (physiotherapy evidence database).
Selection criteria
Randomised and controlled clinical trials evaluating the efficacy and safety of corticosteroid injections for de Quervain’s tenosynovitis.
Data collection and analysis
After screening abstracts of studies identified by the search we obtained full text articles of studies which fulfilled the selection criteria.
We extracted data using a predefined electronic form. We assessed the methodological quality of included trials by using the checklist
developed by Jadad and the Delphi list. We extracted data on the primary outcome measures: treatment success; severity of pain or
tenderness at the radial styloid; functional impairment of the wrist or hand; and outcome of Finkelstein’s test, and the secondary
outcome measures: proportion of patients with side effects; type of side effects and patient satisfaction with injection treatment.
Main results
We found one controlled clinical trial of 18 participants (all pregnant or lactating women) that compared one steroid injection with
methylprednisolone and bupivacaine to splinting with a thumb spica. All patients in the steroid injection group (9/9) achieved complete
relief of pain whereas none of the patients in the thumb spica group (0/9) had complete relief of pain, one to six days after intervention
(number needed to treat to benefit (NNTB) = 1, 95% confidence interval (CI) 0.8 to 1.2). No side effects or local complications of
steroid injection were noted.
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Authors’ conclusions
The efficacy of corticosteroid injections for de Quervain’s tenosynovitis has been studied in only one small controlled clinical trial,
which found steroid injections to be superior to thumb spica splinting. However, the applicability of our findings to daily clinical
practice is limited, as they are based on only one trial with a small number of included participants, the methodological quality was
poor and only pregnant and lactating women participated in the study. No adverse effects were observed.
P L A I N L A N G U A G E S U M M A R Y
Corticosteroid injection for de Quervain’s tenosynovitis
This summary of a Cochrane review presents what we know from research about the effect of Corticosteroid injections for de Quervain’s
tenosynovitis.
This review shows that in people with de Quervain’s tenosynovitis,
We are uncertain whether Corticosteroid injections reduces pain because of the very low quality of the evidence.
What is de Quervain’s tenosynovitis and what are corticosteroid injections?
De Quervain’s tenosynovitis occurs when the tendon in your thumb and wrist becomes inflammed, painful and difficult to move.
A tendon is the part of your body that connects your muscles to your bones. People with de Quervain’s tenosynovitis have pain,
tenderness, and swelling at the base of the thumb, especially when moving their wrist from side to side.
Corticosteroid injections are shots with a needle into a joint (such as your wrist) or a tendon. Corticosteroids may work by reducing
the inflammation of your wrist or thumb. The injection itself might also help to relieve the pressure on the tendon.
B A C K G R O U N D
De Quervain’s tenosynovitis is a disorder that is characterised by
pain, tenderness and swelling over the thumb side of the wrist (at
the radial styloid process). It is especially associated with sideward
movements of the wrist and often leads to impairment of thumb
function. It is caused by impaired gliding of the tendons of the
abductor pollicis longus (APL) and extensor pollicis brevis (EPB)
muscles. These two tendons have almost the same function: the
movement of the thumb away from the hand in the plane of the
hand. This impaired gliding ismost probably caused by thickening
of the extensor retinaculum of the wrist (the thickened part of
the general tendon sheath that holds the tendons of the extensor
muscles in place).
De Quervain, a Swiss physician, is given credit for first describing
this condition with a report of five cases in 1895 and eight addi-
tional cases in 1912. Although the term stenosing tenosynovitis
is frequently used, the pathophysiology of de Quervain’s disease
does not involve inflammation. Onhistopathological examination
the predominant features are degenerative changes (myxoid de-
generation, fibrocartilagenous metaplasia and deposition of mu-
copolysaccharide). Pain is most probably elicited by mechanical
impingement between the tendon and its narrowed fibro-osseous
canal resulting in stimulation of nociceptors (Clarke 1998).
De Quervain’s tenosynovitis has tended to fall under umbrella
terms such as repetitive strain injury (RSI) and work-related mus-
culoskeletal disorders of the upper limb (WRMSDs-UL) (Sluiter
2001; Yassi 1997). Several authors have proposed models in which
complex interactions between genetic factors, biomechanical fac-
tors, biophysical characteristics and the psychological profile of a
patient lead to WRMSDs (Aptel 2002; Kumar 2001). In a litera-
ture review of epidemiological studies strong evidence was found
for links between some biomechanical risk factors and muscu-
loskeletal disorders of the upper limb (Bernard 1997). Some have
questioned the role of work in causing de Quervain’s tenosynovitis
(Kay 2000).
In a large community based study from the United Kingdom, the
prevalence of de Quervain’s tenosynovitis was found to be 0.5%
in men and 1.3% in women (Walker-Bone 2004). Specific up-
per limb disorders, such as de Quervain’s tenosynovitis, tended to
cluster within individuals more often than would be expected by
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chance and they were associated with greater disability and more
use of health services than was nonspecific pain (Walker-Bone
2004). Data from the 1998 National Health Interview Survey/
Occupational Health Supplement in the United States show an
estimated 12-month period prevalence of tendinitis of the hand,
wrist and elbow (including tendinitis, synovitis, tenosynovitis, de
Quervain’s disease and epicondylitis) of 0.31% amongst 127 mil-
lion workers (Tanaka 2001). The annual cost of all WRMDs is
estimated to range from 13 to 20 billion US dollars in the United
States (Aptel 2002).
Diagnosis of de Quervain’s tenosynovitis is made by history and
physical examination (Moore 1997). Symptoms consist of pain or
tenderness at the radial styloid sometimes radiating to the thumb,
forearm or shoulder, and on physical examination there might be
swelling at the radial styloid with tenderness and crepitations on
palpation. Finkelstein’s test (deviating the wrist to the ulnar side,
while grasping the thumb, resulting in pain) is typically positive. A
positive Finkelstein’s test has a between-observer repeatability (k)
of 0.79 (Palmer 2000). Unfortunately there is no gold standard
diagnostic confirmatory test for deQuervain’s tenosynovitis. In the
literature a variety of terminology (e.g. tendinitis, peritendinitis,
tenosynovitis, tenovaginitis) and case definitions are used for this
condition. In 1998, 2001 and 2007 efforts were made to construct
reliable classifications and case definitions for soft tissue rheumatic
disorders of the upper limb, including de Quervain’s tenosynovitis
(Harrington 1998; Sluiter 2001; Huisstede 2007).
De Quervain’s tenosynovitis can be treated by operative and non-
operative treatment.Operative therapy (slitting or removing a strip
of the tendon sheet) has been reported to be effective with a 91%
cure rate, but is more invasive and associated with higher costs and
the possibility of surgical complications (Ta 1999). Local anaes-
thetic and corticosteroid injections for musculoskeletal diseases
became popular in the 1950s. The effectiveness of injection ther-
apy is often attributed to the anti-inflammatory effects of corticos-
teroids but the exact mechanism of action remains unclear since
on histopathologic examination inflammation cannot be demon-
strated. In a systematic review of the effectiveness of corticosteroid
injection for de Quervain’s tenosynovitis, which included seven
observational studies with a total of 459 wrists, 83% of the 226
wrists that received injection alone were cured, 61% of the 101
wrists that received injection and splint immobilisation were cured
and 14% of those who received splinting alone were cured (Richie
2003).Other conservative treatmentmodalities, such as heat, cold,
heat induction, strapping, splints, rest, massage, counter-irritants
and medications were found not to be effective (Moore 1997).
There are no reports available that describe the natural course of
untreated de Quervain’s tenosynovitis. Potential complications of
local corticosteroid injections for musculoskeletal disorders such
as de Quervain’s tenosynovitis are local infection, post injection
steroid flare (temporary worsening of pain in the first 24 to 36
hours after injection), atrophy (thinning) of subcutaneous fat, lo-
cal depigmentation of the skin and, very rarely, tendon rupture
(Cardone 2002).
De Quervain’s tenosynovitis can lead to marked disability and ab-
sence from work due to impaired functioning of the hand. Lo-
cal corticosteroid injection has been suggested to be effective, safe
and easy to apply therefore it was decided to perform a systematic
review of the efficacy and safety of corticosteroid injections for
de Quervain’s tenosynovitis. Although the effectiveness of corti-
costeroid injections has been addressed in a previous systematic
review (Richie 2003) a more comprehensive review, according to
the standards of the Cochrane Collaboration, can provide valu-
able additional information. The Richie 2003 review has major
shortcomings: None of the identified studies were randomised or
used controls, pooling of data was not performed in a standardised
manner and it was stated only that the “MEDLINE and Ovid
databases were searched”. Search strategy, selection criteria and
method of data synthesis were not specified and it was not clear
which databases were searched on the Ovid platform.
O B J E C T I V E S
To review systematically the evidence from clinical trials on the
efficacy and safety of corticosteroid injections for de Quervain’s
tenosynovitis in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) and controlled clinical tri-
als (CCTs) evaluating injection therapy with corticosteroids were
included in this review.
Types of participants
We only included studies containing a study population with a
clinical diagnosis of de Quervain’s tenosynovitis (pain and tender-
ness over the radial styloid and either pain at the radial styloid
reproduced by resisted thumb extension or a positive Finkelstein’s
test result).We excluded studies addressing treatment of DeQuer-
vain’s tenosynovitis of infectious origin.
Types of interventions
We only included studies evaluating the effectiveness of local cor-
ticosteroid injections. The corticosteroid could be of any volume,
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type and concentration, a local anaesthetic agent could be added
or not, and any injection technique could be used. We planned
to include studies comparing corticosteroid injection to placebo,
injection with local anaesthetic, injection with a different type of
steroid, splinting, systemic analgesics (including NSAIDs), sys-
temic steroids, surgery, combination treatments or no interven-
tion.
Types of outcome measures
Primary outcomes
• Treatment success: yes or no (we anticipated that the
definition of treatment success may vary across trials).
• Severity of pain or tenderness at the radial styloid.
• Finkelstein’s test negative: yes or no.
• Functional status of the finger (using validated instruments
to measure hand function).
• Proportion of patients with adverse effects of steroid
injection.
Secondary outcomes
• Patient satisfaction (using validated questionnaires).
Search methods for identification of studies
We searched the following electronic databases:
• the Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2009, Issue 2);
• MEDLINE (1966 to April 2009, Ovid platform);
• EMBASE (1956 to April 2009, Ovid platform);
• CINAHL (1982 to April 2009, Ovid platform);
• AMED (1985 to April 2009, Ovid platform);
• PEDro, the physiotherapy evidence database (
www.pedro.org.au)
• DARE (the Database of Abstracts of Reviews of
Effectiveness; via The Cochrane Library 2009, Issue 2);
• Dissertation abstracts.
The search strategy was developed for MEDLINE and modified
as necessary for the other databases.
Complete search strategies for each database are provided in
Appendix 1; Appendix 2; Appendix 3; Appendix 4; Appendix 5;
Appendix 6; Appendix 7; Appendix 8. We checked the references
of all relevant publications (RCTs and reviews) to identify addi-
tional trials. We contacted content experts for unpublished data.
There were no language restrictions.
Data collection and analysis
Trial selection
Two review authors independently selected trials for inclusion in
this review based on the content of title and abstracts obtained
through electronic searching of the databases. Each review author’s
selection was compared. We resolved any discrepancies in opinion
about eligibility of a trial for this review by discussion and con-
sensus between the two review authors.
Quality appraisal
Two review authors independently extracted all data. We assessed
each trial using a combination of an established quality assess-
ment tool developed by Jadad (Jadad 1996) and the Delphi list
(Verhagen 1998). The quality items assessed were:
1. randomisation;
2. concealment of allocation;
3. blinding of outcome assessor, care provider and patient;
4. reporting of withdrawals and drop-outs;
5. similarity of groups at baseline regarding the most
important prognostic indicators;
6. specification of eligibility criteria;
7. availability of point estimates and measures of variability of
primary outcome measures;
8. use of intention-to-treat analysis.
Each criterion was rated as adequate, inadequate or unclear (if
insufficient information was presented).
Data extraction
Two authors extracted details of the study population, interven-
tions, treatment periods, length of follow up, complications, base-
line demographic data and baseline and end of study outcomes
using a pre-defined electronic form. We arbitrarily defined short-
term outcomes as outcomes up to three months after the interven-
tion and long-term outcomes as outcomes one year post-interven-
tion or later. Referring back to the original article and establishing
consensus resolved differences in data extraction. We consulted a
third author to help resolve differences.
Data analysis
For continuous data, we planned to calculate mean differences
(MD) for outcomes measured using the same scale, and when the
same outcomes were measured using different scales we were to
use standardised mean differences (SMD). We planned to calcu-
late absolute and relative difference in the change from baseline
for continuous outcomes. We were to calculate absolute benefit as
the improvement in the treatment group minus the improvement
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in the control group in original units. We were to calculate rela-
tive difference in the change from baseline as the absolute benefit
divided by the baseline mean.
For dichotomous data, we planned to present the results for each
study as relative risk and the number needed to treat. However, we
made a post hoc decision to present the results as risk difference
(RD) and number needed to treat (NNT) to benefit, as only one
eligible studywas identified and no events (treatment success) were
observed in any of the participants in the control group.
Heterogeneity
To assess heterogeneity of trial results we planned to use the
CochraneQ-test and the I2 statistic. In case of significant statistical
heterogeneity we planned to explore potential sources by subgroup
analysis. Since clinical and methodological diversity always occur
in a meta-analysis, statistical heterogeneity is inevitable (Higgins
2003). The test for heterogeneity is irrelevant to the choice of anal-
ysis; accordingly we used the random-effects model by default as
it is identical to the fixed-effect model if there is no heterogeneity
(I2 = 0%). In order to assess and quantify the possible magnitude
of inconsistency (i.e. heterogeneity) across studies, we used the I
2 statistic with a rough guide for interpretation as follows: 0% to
40% might not be important; 30% to 60% may represent mod-
erate heterogeneity; 50% to 90% may represent substantial het-
erogeneity; 75% to 100% represents considerable heterogeneity.
Subgroup analysis
We planned the following subgroup analyses:
• duration of symptoms at baseline: short if symptoms were
present for up to four weeks, intermediate if symptoms were
present for one month to one year, and long if symptoms were
present for one year or longer;
• trial design: RCT or controlled clinical trial.
Clinical relevance tables
We compiled a clinical relevance table for the primary outcomes to
improve the readability of the review (Table 1). For dichotomous
outcomes, we calculated the absolute risk difference using the risk
difference (RD) statistic, and the relative per cent change using
the relative risk (RR) - 1 statistic in RevMan 5 (RevMan 2008).
We determined the number needed to treat (NNT) by calculating
the inverse of the risk difference (RD).
Grading of evidence
Finally we graded the evidence obtained in this systematic review
according to the conventions proposed by the Cochrane Muscu-
loskeletal Group (Tugwell 2004).
Platinum: a published systematic review that has at least two in-
dividual controlled trials each satisfying the following:
• sample sizes of at least 50 per group - if these do not find a
statistically significant difference, they are adequately powered
for a 20% relative difference in the relevant outcome;
• blinding of patients and assessors for outcomes;
• handling of withdrawals with > 80% follow up
(imputations based on methods such as Last Observation
Carried Forward (LOCF) are acceptable);
• concealment of treatment allocation.
Gold: at least one randomised clinical trial meeting all of the fol-
lowing criteria for the major outcome(s) as reported:
• sample sizes of at least 50 per group - if these do not find a
statistically significant difference, they are adequately powered
for a 20% relative difference in the relevant outcome;
• blinding of patients and assessors for outcomes;
• handling of withdrawals with > 80% follow up
(imputations based on methods such as LOCF are acceptable);
• concealment of treatment allocation.
Silver: a systematic review or randomised trial that does not meet
the above criteria. Silver ranking would also include evidence from
at least one study of non-randomised cohorts that did and did
not receive the therapy, or evidence from at least one high quality
case-control study. A randomised trial with a ’head-to-head’ com-
parison of agents would be considered silver level ranking unless
a reference was provided to a comparison of one of the agents to
placebo showing at least a 20% relative difference.
Bronze: the bronze ranking is given to evidence from at least one
high quality case series without controls (including simple before/
after studies in which patients act as their own control) or if the
conclusion is derived from expert opinion based on clinical ex-
perience without reference to any of the foregoing (for example,
argument from physiology, bench research or first principles).
This review will be updated two years after publication.
R E S U L T S
Description of studies
The electronic search resulted in retrieval of a total of 561 titles.We
found no titles in PEDro. After screening the titles and abstracts,
we selected five possible studies for further evaluation (Avci 2002;
Goldfarb 2007; Jirarattanaphochai 2004; Kosuwon 1996; Weiss
1994). We retrieved full text articles of these five studies. We ex-
cluded four studies: one appeared to be a retrospective cohort study
(Weiss 1994) and three studies did not study the comparison of
interest (in one study steroid injection was compared to steroid in-
jectionwith additional oral medication (Jirarattanaphochai 2004),
in one study steroid injection was compared to steroid injection
followed by wrist immobilisation in a splint (Kosuwon 1996) and
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in one injectionwith steroid, lidocaine and bupivacaine alone were
compared to injections with steroid, lidocaine, bupivacaine and
bicarbonate (Goldfarb 2007).
We were also aware of an ongoing randomised controlled trial
assessing the effectiveness of corticosteroid injections in the setting
of primary care, but the results of this study were not published
when our search was performed (see ’Characteristics of ongoing
studies’).
The included study (Avci 2002) was a controlled clinical study
including 19 wrists in 18 pregnant or lactating women (five wrists
of pregnant women, 14 of lactating women). It compared one
injection of 0.25 ml of methylprednisolone (10 mg) with 0.5%
bupivacaine to thumb spica splinting in a secondary care setting.
Injections were given into the tendon-sheath. Diagnostic criteria
were a tender nodule over the radial styloid and a positive Finkel-
stein’s test result. The main outcome (complete relief of pain and
a negative Finkelstein’s test result) was measured one to six days
after injection.
Risk of bias in included studies
The included study used pseudo-randomisation (participants were
randomised according to their order of application), there was no
description of allocation concealment (but since there was alter-
nate allocation it is likely that allocation concealment was inade-
quate) and participants, care providers and outcome assessors were
not blinded. Withdrawals and drop-outs were reported and an in-
tention-to-treat analysis was used, but it was not clear whether the
two treatment groups were similar at baseline assessment regard-
ing important prognostic indicators. The main outcome measure
was “complete pain relief ”. No point estimates and measures of
variability were presented for the outcome measures.
Effects of interventions
The only primary outcome measure assessed was complete relief
of pain. All patients in the steroid injection group (9/9) achieved
complete relief of pain and none of the patients in the thumb spica
group (0/9) had complete relief of pain, one to six days after the
intervention. The number needed to treat was thus 1 (95%CI 0.8
to 1.2). No side effects or local complications of steroid injection
were noted (Analysis 1.1) (Table 1).
D I S C U S S I O N
In this review, which includes only one small controlled clinical
trial (Avci 2002) with 18 participants, we found silver level evi-
dence for the superiority of corticosteroid injection over thumb
spica splinting within six days of injection. The number needed
to treat was 1 for this intervention, which means that every partic-
ipant treated with local corticosteroid injection for de Quervain’s
tenosynovitis achieves complete relief of pain within six days of
treatment, while none of the participants treated with thumb spica
splints achieves complete relief of pain.
The large effect size of steroid injections for de Quervain’ tenosyn-
ovitis reported in this review is consistent with findings in another
systematic review which included only non-randomised studies
(Richie 2003), in which a cure rate of 83% in 459 wrists receiv-
ing steroid injections alone was reported and no side effects were
observed.
There are several important limitations to this review. Only one
study was found, which included only 18 participants. The risk
of bias may be considerable since the included study used pseudo-
randomisation and allocation concealment and blinding were in-
adequate. The study also included a selected patient population
(pregnant and lactating women), was carried out in a selected
healthcare setting (specialist hospital care) and compared the ef-
fectiveness of local corticosteroid only to thumb spica splinting;
generalisability was therefore limited. Long-term treatment effects
were not assessed. Given the weak evidence base it is not possible
to draw any firm conclusions regarding the effectiveness of steroid
injections for de Quervain tenosynovitis. The applicability of the
findings of this review to daily clinical practice is therefore limited
and needs to be confirmed in larger, better designed randomised
controlled trials of longer duration.
Several other issues regarding steroid injections for de Quervain’s
tenosynovitis remain to be clarified. There is no universally agreed
case definition and there are no validated outcome measures for
research purposes. Furthermore, the efficacy, safety and cost-effec-
tiveness of steroid injection has never been compared directly to
surgical therapy or a wait and see strategy. Long-term effectiveness
has also never been studied.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is silver level evidence that corticosteroid injections are su-
perior to thumb spica splinting for relieving pain in the treat-
ment of de Quervain’s tenosynovitis, but the evidence is based on
one very small controlled clinical trial of short duration and poor
methodological quality, which included only pregnant and lactat-
ing women.
Implications for research
A case definition for de Quervain’s tenosynovitis should be formu-
lated for research purposes. Validated and relevant outcome mea-
sures for interventions for de Quervain’s tenosynovitis should be
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developed. Future randomised controlled trials should have ade-
quate sample sizes, better methodological quality (including ade-
quate randomisation procedures and allocation concealment) and
also study other types of participants (besides pregnant and lactat-
ing women). Longer follow up is needed and the findings should
be reported according to the CONSORT statement. Studies are
needed which compare corticosteroid injections to placebo and to
surgery, and which compare different types and dosages of corti-
costeroids. Future studies should also address the natural course
of de Quervain’s tenosynovitis.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Avci 2002
Methods Randomised controlled study: allocation of intervention based on order of application
Method of blinding unclear
Parallel groups
Participants Secondary care
Pregnant (5 participants) or lactating (13 participants) women
Mean age 28 years (range: 20 to 36)
Inclusion criteria: tender nodule over the radial styloid and a positive Finkelstein’s test result
Exclusion criteria: a past history of similar symptoms, systemic disorders such as diabetes or connective
tissue diseases that cause tenosynovitis
Flow of participants: 18 enrolled, 18 randomised
9 randomised to corticosteroid + anaesthetic injection versus 9 randomised to thumb spica splinting
18 received allocated intervention
0 lost to follow up
18 participants analysed
Interventions Group 1: 1 injection of 0.25 ml methylprednisolone (10 mg) with 0.5% bupivacaine into the tendon
sheath
Group 2: thumb spica splints worn during daytime
Outcomes Definition of treatment success: complete relief of pain and a negative Finkelstein test result
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? High risk Unlikely to be adequately concealed, as allocation
of intervention based on order of application
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Goldfarb 2007 Not comparison of interest: injection with steroid, lidocaine and bupivacaine alone was compared to
injection with steroid, lidocaine, bupivacaine and bicarbonate
Jirarattanaphochai 2004 Not comparison of interest: steroid injection was compared to steroid injection with additional oral
medication
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(Continued)
Kosuwon 1996 Not comparison of interest: steroid injection was compared to steroid injection followed by wrist immo-
bilisation in a splint
Weiss 1994 Not a randomised study: retrospective cohort study
Characteristics of ongoing studies [ordered by study ID]
Peters 2007
Trial name or title The Groningen Hand and Wrist Injection Therapy Trial
Methods Randomised controlled study




Inclusion criteria: a history of radial styloid tenderness and a positive Finkelstein’s test and/or crepitus over
APB and EPL tendons
Exclusion criteria: less than 18 years of age, presence of an absolute contraindication for corticosteroid
injection, prior treatment in the last 6 months with steroid injection and/ or surgery at the same anatomical
location, possible traumatic or neoplastic origin of symptoms, inability to fill in follow-up forms or absence
of self-determination in the participant
Interventions Group 1: 1 or 2 injections of 1 ml triamcinolonacetonide 10 mg/ml
Group 2: 1 or 2 injections of 1 ml 0.9 % NaCl
Outcomes 1. Direct treatment response (consensus between physician and patient): no response; partial response,
but not satisfactory, warranting further treatment; partial response, satisfactory, not warranting further
treatment; complete resolution of symptoms and signs)
2. Perceived improvement (by patient): much worse, worse, not better/not worse, better, much better
3. Severity of pain at the radial styloid: 11-point numeric rating scale: 0 to 10
4. Functional improvement using the sub-items hand and finger function of the Dutch version of the
second version of the Arthritis Impact Measurement Scale (DUTCH AIMS-2)
Starting date 2003
Contact information Cyriac Peters-Veluthamaningal, general practitioner. Department of General Practice, University Medical
Center Groningen, Antonius Deusiglaan 1, 9713 AV Groningen, the Netherlands. E-mail: raju@dds.nl
Notes -
APB = abductor pollicis longus
EPL= extensor pollicis brevis
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D A T A A N D A N A L Y S E S
Comparison 1. 0.25 ml of methylprednisolone (10 mg) + 0.5% bupivacaine vs thumb spica splint




participants Statistical method Effect size
1 Complete relief of symptoms 1 Risk Difference (M-H, Random, 95% CI) Subtotals only
Analysis 1.1. Comparison 1 0.25 ml of methylprednisolone (10 mg) + 0.5% bupivacaine vs thumb spica
splint, Outcome 1 Complete relief of symptoms.
Review: Corticosteroid injection for de Quervain’s tenosynovitis
Comparison: 1 0.25 ml of methylprednisolone (10 mg) + 0.5% bupivacaine vs thumb spica splint
Outcome: 1 Complete relief of symptoms
Study or subgroup
Corticosteroid












Avci 2002 9/9 0/9 1.00 [ 0.81, 1.19 ]
-2 -1 0 1 2
Favours splint Favours injection
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A D D I T I O N A L T A B L E S
Table 1. Clinical relevance for complete pain relief



























RD = risk difference
I = Improvement
95% CI = 95% confidence interval
NNTB = number needed to treat to benefit
A P P E N D I C E S








8. exp Cumulative Trauma Disorders/
9. overuse syndrome$.tw.
10. repetit$ strain injur$.tw.












23. (steroid$ adj2 inject$).tw.
24. or/13-23
25. 12 and 24
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8. exp Cumulative Trauma Disorder/
9. overuse syndrome$.tw.
10. repetit$ strain injur$.tw.












23. (steroid$ adj2 inject$).tw.
24. or/13-23
25. 12 and 24
26. random$.ti,ab.
27. factorial$.ti,ab.
28. (crossover$ or cross over$ or cross-over$).ti,ab.
29. placebo$.ti,ab.
30. (doubl$ adj blind$).ti,ab.





36. double blind procedure.sh.
37. randomized controlled trial.sh.
38. single blind procedure.sh.
39. or/26-38
40. exp animal/ or nonhuman/ or exp animal experiment/
41. exp human/
42. 40 and 41
43. 40 not 42
44. 39 not 43
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8. exp Cumulative Trauma Disorders/
9. overuse syndrome$.tw.
10. repetit$ strain injur$.tw.












23. (steroid$ adj2 inject$).tw.
24. or/13-23
25. 12 and 24








8 repetit$ strain injur$.tw.
9 repetit$ motion disorder$.tw.
10 or/1-9






17 (steroid$ adj2 inject$).tw.
18 or/11-17
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Appendix 5. PEDro search strategy
Search 1
Tenosynovitis in Abstract or title and Body Part = hand or wrist
Search 2
Tendon in Abstract or title and Body Part = hand or wrist
Search 3
Quervain* in Abstract or title
Appendix 6. CENTRAL search strategy
#1 MeSH descriptor Tenosynovitis explode all trees in MeSH products?
#2 tenosynovitis in All Fields in all products?
#3 MeSH descriptor Tendinitis explode all trees in MeSH products?
#4 tendonitis or tendinitis in All Fields in all products?
#5 peritendinitis in All Fields in all products?
#6 tendovaginitis in All Fields in all products?
#7 quervain* in All Fields in all products?
#8 MeSH descriptor Cumulative Trauma Disorders explode all trees in MeSH products?
#9 overuse syndrome* in All Fields in all products?
#10 repetit* next strain next injur* in All Fields in all products?
#11 repetit* next motion next disorder* in All Fields in all products?
#12 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11)?
#13 MeSH descriptor Glucocorticoids explode all trees in MeSH products?
#14 glucocorticoid* in All Fields in all products?
#15 MeSH descriptor Adrenal Cortex Hormones explode all trees in MeSH products?
#16 corticoster* in All Fields in all products?
#17 MeSH descriptor Methylprednisolone explode all trees in MeSH products?
#18 Methylprednisolone in All Fields in all products?
#19 betamethasone in All Fields in all products?
#20 MeSH descriptor Betamethasone explode all trees in MeSH products?
#21 MeSH descriptor Triamcinolone explode all trees in MeSH products?
#22 TRIAMCINOLONE in All Fields in all products?
#23 steroid* near/2 inject* in All Fields in all products?
#24 (#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #21 OR #22 OR #23)?
#25 (#12 AND #24)
Appendix 7. DARE search strategy
#1 MeSH descriptor Tenosynovitis explode all trees in MeSH products?
#2 tenosynovitis in All Fields in all products?
#3 MeSH descriptor Tendinitis explode all trees in MeSH products?
#4 tendonitis or tendinitis in All Fields in all products?
#5 peritendinitis in All Fields in all products?
#6 tendovaginitis in All Fields in all products?
#7 quervain* in All Fields in all products?
#8 MeSH descriptor Cumulative Trauma Disorders explode all trees in MeSH products?
#9 overuse syndrome* in All Fields in all products?
#10 repetit* next strain next injur* in All Fields in all products?
#11 repetit* next motion next disorder* in All Fields in all products?
#12 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11)?
#13 MeSH descriptor Glucocorticoids explode all trees in MeSH products?
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#14 glucocorticoid* in All Fields in all products?
#15 MeSH descriptor Adrenal Cortex Hormones explode all trees in MeSH products?
#16 corticoster* in All Fields in all products?
#17 MeSH descriptor Methylprednisolone explode all trees in MeSH products?
#18 Methylprednisolone in All Fields in all products?
#19 betamethasone in All Fields in all products?
#20 MeSH descriptor Betamethasone explode all trees in MeSH products?
#21 MeSH descriptor Triamcinolone explode all trees in MeSH products?
#22 TRIAMCINOLONE in All Fields in all products?
#23 steroid* near/2 inject* in All Fields in all products?
#24 (#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #21 OR #22 OR #23)?
#25 (#12 AND #24)
Appendix 8. Dissertation abstracts search strategy
(Quervain* OR overuse syndrome* OR repetitive strain OR repetitive motion) AND (glucocorticoid* OR corticoster*)
H I S T O R Y
Protocol first published: Issue 1, 2006
Review first published: Issue 3, 2009
Date Event Description
17 July 2008 Amended Converted to new review format. CMSG ID A022-R
C O N T R I B U T I O N S O F A U T H O R S
CP: main author
DW: text of review, data extraction and analysis
JW: data extraction and analysis
BM: selection of studies
D E C L A R A T I O N S O F I N T E R E S T
CP has conducted a randomised controlled trial (Groningen Hand and Wrist Injection Therapy Trial - HAWITT) assessing the
efficacy and safety of corticosteroid injections for trigger finger, de Quervain’s tenosynovitis and carpal tunnel syndrome in a primary
care population. The HAWITT-trial is sponsored by an unrestricted educational grant by the pharmaceutical company Bristol-Myers
Squibb.
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S O U R C E S O F S U P P O R T
Internal sources
• Department of General Practice, University Medical Center Groningen, Netherlands.
• EMGO Institute, VU University Medical Center Amsterdam, Netherlands.
External sources
• No sources of support supplied
I N D E X T E R M S
Medical Subject Headings (MeSH)
Adrenal Cortex Hormones [∗therapeutic use]; Anti-Inflammatory Agents [∗therapeutic use]; De Quervain Disease [∗drug therapy;
therapy]; Methylprednisolone [∗therapeutic use]; Pregnancy Complications [drug therapy; therapy]; Splints
MeSH check words
Female; Humans; Pregnancy
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